ES2751925T5 - Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor - Google Patents

Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Download PDF

Info

Publication number
ES2751925T5
ES2751925T5 ES15734713T ES15734713T ES2751925T5 ES 2751925 T5 ES2751925 T5 ES 2751925T5 ES 15734713 T ES15734713 T ES 15734713T ES 15734713 T ES15734713 T ES 15734713T ES 2751925 T5 ES2751925 T5 ES 2751925T5
Authority
ES
Spain
Prior art keywords
braf
inhibitor
mutation
nras
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15734713T
Other languages
English (en)
Spanish (es)
Other versions
ES2751925T3 (es
Inventor
Mitchell Paul Levesque
Reinhard Dummer
Daniel Widmer
Marieke Ineke Geertje Raaijmakers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universitaet Institut fuer Medizinische Virologie
Original Assignee
Zurich Universitaet Institut fuer Medizinische Virologie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51210291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2751925(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zurich Universitaet Institut fuer Medizinische Virologie filed Critical Zurich Universitaet Institut fuer Medizinische Virologie
Publication of ES2751925T3 publication Critical patent/ES2751925T3/es
Application granted granted Critical
Publication of ES2751925T5 publication Critical patent/ES2751925T5/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
ES15734713T 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor Active ES2751925T5 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14176944 2014-07-14
PCT/EP2015/065986 WO2016008853A1 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Publications (2)

Publication Number Publication Date
ES2751925T3 ES2751925T3 (es) 2020-04-02
ES2751925T5 true ES2751925T5 (en) 2025-05-13

Family

ID=51210291

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15734713T Active ES2751925T5 (en) 2014-07-14 2015-07-13 Means and methods for identifying a patient having a braf-positive cancer as a non-responder to a braf inhibitor and as a responder to an mapk/erk inhibitor

Country Status (7)

Country Link
US (1) US20190194757A1 (enExample)
EP (1) EP3169797B2 (enExample)
JP (1) JP7036594B2 (enExample)
CN (1) CN107148481A (enExample)
CA (1) CA2953732C (enExample)
ES (1) ES2751925T5 (enExample)
WO (1) WO2016008853A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
JP7405408B2 (ja) * 2017-05-16 2023-12-26 バイオメッド バレー ディスカバリーズ，インコーポレイティド 異型ｂｒａｆ変異を有するがんを処置するための組成物および方法
CN112795647B (zh) * 2019-11-14 2022-08-16 北京肿瘤医院(北京大学肿瘤医院) 一种肿瘤标志物及其应用
CN111020033A (zh) * 2019-12-24 2020-04-17 中山大学达安基因股份有限公司 多重检测braf基因突变的试剂盒及方法
CN118043654A (zh) * 2021-06-23 2024-05-14 皇家墨尔本理工大学 用于检测核酸的电导式传感器及其检测方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
EP3249053A1 (en) * 2009-03-27 2017-11-29 Life Technologies Corporation Methods, compositions, and kits for detecting allelic variants
WO2012058532A2 (en) * 2010-10-28 2012-05-03 Yale University Methods and compositions for assessing and treating cancer
EP2635286A4 (en) 2010-11-05 2014-11-12 Glaxosmithkline Ip No 2 Ltd METHOD FOR THE TREATMENT OF CANCER
WO2012068468A1 (en) * 2010-11-19 2012-05-24 Glaxosmithkline Llc Method of treatment with braf inhibitor
WO2012068562A2 (en) 2010-11-19 2012-05-24 The Regents Of The University Of California Compositions and methods for detection and treatment of b-raf inhibitor-resistant melanomas
WO2014009319A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh Indolinone derivatives anticancer compounds
WO2014009318A1 (en) * 2012-07-11 2014-01-16 Boehringer Ingelheim International Gmbh 3-{3-[1 -(4-dimethylaminomethyl-phenylamino)-1 -phenyl-meth-(z)-ylidene]-2-oxo-2,3-dihydro-1 h-indol-6-yll-propynoic acid ethylamide and its use in the treatment of cancer
CA2886397A1 (en) * 2012-09-26 2014-04-03 Insight Genetics, Inc. Methods and compositions relating to next generation sequencing for genetic testing in alk related cancers

Also Published As

Publication number Publication date
JP2017529094A (ja) 2017-10-05
US20190194757A1 (en) 2019-06-27
EP3169797B1 (en) 2019-08-21
EP3169797A1 (en) 2017-05-24
ES2751925T3 (es) 2020-04-02
JP7036594B2 (ja) 2022-03-15
CA2953732C (en) 2023-09-26
CA2953732A1 (en) 2016-01-21
WO2016008853A1 (en) 2016-01-21
EP3169797B2 (en) 2025-02-19
CN107148481A (zh) 2017-09-08

Similar Documents

Publication Publication Date Title
JP7759177B2 (ja) 癌の治療方法
Nalejska et al. Prognostic and predictive biomarkers: tools in personalized oncology
Skaro et al. Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms
US9133523B2 (en) Compositions and methods for detecting cancer metastasis
EP3524698A1 (en) Method for the prognosis and treatment of cancer metastasis
US10473662B2 (en) Diagnostic and prognostic markers for cancer
ES2751925T3 (es) Medios y procedimientos para identificar a un paciente que tiene un cáncer positivo para BRAF como un paciente que no responde al tratamiento con un inhibidor de BRAF y como un paciente que responde al tratamiento con un inhibidor de MAPK/ERK
Liu et al. miR-31-5p-DMD axis as a novel biomarker for predicting the development and prognosis of sporadic early-onset colorectal cancer
WO2014135655A1 (en) Compositions and methods for treating muscle-invasive bladder cancer
Tanigawa et al. MicroRNA signature of small‐cell lung cancer after treatment failure: impact on oncogenic targets by miR‐30a‐3p control
WO2019213689A1 (en) Determining cancer responsiveness to treatment
US10676792B2 (en) Prognostic and diagnostic methods for colorectal cancer
Abdul et al. Molecular characterization of somatic alterations in Dukes’ B and C colorectal cancers by targeted sequencing
US20120309640A1 (en) Diagnostic and Prognostic Markers for Cancer
Feng et al. Identification of topoisomerase 2A as a novel bone metastasis-related gene in liver hepatocellular carcinoma
WO2022159852A1 (en) Methods and compositions for treating adenoid cystic carcinoma
CN114502745A (zh) 利用脱氧核糖核酸甲基化突变的抗癌免疫治疗反应性预测方法
ES2792150A1 (es) Metodo para predecir y/o diagnosticar la metastasis del cancer
EP3041956B1 (en) Ddx43 as a biomarker of resistance to mek1/2 inhibitors
Cheng et al. Cell-cycle-related transcriptional factor DLX4: a novel prognostic biomarker and potential therapeutic target in colorectal cancer
Ouyang et al. Long non-coding RNA AFAP1-AS1 promotes alternative splicing of AXIN2 by facilitating SRSFs phase separation to induce drug resistance in lung adenocarcinoma
US11697845B2 (en) Directing treatments for glioblastoma based on identifying a somatic structural rearrangement upstream from TERT gene
US20240026458A1 (en) Method for Determining Sensitivity to an Antineoplastic Agent
Talaat et al. OPEN ACCESS EDITED BY
Nagelberg et al. Integrative genomics identifies SHPRH as a tumor suppressor gene in lung adenocarcinoma that regulates DNA damage response